The inhibition of growth by SPHK1-I and SPHK2-I of primary neoplastic MCs from patients and of D816V-KIT MCs in vivo support the conclusion that SPHK inhibitors are appropriate candidates to consider for clinical applications in the treatment of mastocytosis. This evidence concerns the gene SPHK2 and mastocytosis.